This page was translated automatically from Turkish. Read the original

This page is an AI-assisted Turkish summary of the study presented at the 26th World Congress of Psychiatry. The study belongs to the presenting authors; please refer to the original source when citing it.

A targeted omics approach to psychiatric disorders

Targeted omics approach in psychiatric disorders

Plasma metabolomic and proteomic profiles distinguish patients from controls but do not show clear differentiation among schizophrenia, bipolar disorder, and schizoaffective disorder.

The aim is to identify disease-associated molecular patterns in schizophrenia (SCZ), bipolar disorder (BD), and schizoaffective disorder (SAD), whose diagnoses rely largely on clinical observation and self-report, and to contribute to understanding their underlying pathophysiology. In this study, plasma samples collected from patients were analyzed using targeted metabolomic and proteomic approaches. A total of 26 patients with BD, 34 with SCZ, and 16 with SAD were enrolled. The scores plot showed clear differences in metabolic and inflammatory profiles between controls and patients; the lack of clear separation among the three diagnostic subgroups suggested that these disorders share common biological profiles. Components that differed between controls and patients included acylcarnitines, amino acids, biogenic amines, glycerophospholipids, and proinflammatory cytokines. The principal metabolites driving this distinction were putrescine, glycerophospholipids (PC ae C40:3, PC ae C38:2, PC ae C44:3, PC ae C38:3, PC aa C42:4), sphingomyelins (SM (OH) C22:2, SM C26:1, SM C20:2), creatinine, acylcarnitines (C18:1-OH, C5-M-DC, C3-DC), and amino acids (valine, tryptophan, phenylalanine, tyrosine, glutamine, and taurine). The authors view this study as a step toward overcoming the limitations of current diagnostic approaches in severe psychiatric disorders and refining diagnosis and treatment through omics sciences.

All WCP 2026 summaries